SZodixStudyAcademic Library
ShelvesOpen access
Study · an open academic library·Metadata from OpenAlex (CC0)·Shelves·OpenAlex metadata, de-duplicated
Value-Based Cancer Care
2 references·3 citing·21 second hop
Value-Based Cancer Care (2015)Value-Based Cancer CareAmerican Society of Clinical Oncology Statement: A Conceptual Framework to Assess the Value of Cancer Treatment Options (2015)American Society of Clinical …American Society of Clinical Oncology Identifies Five Key Opportunities to Improve Care and Reduce Costs: The Top Five List for Oncology (2012)American Society of Clinical …Value-Based Healthcare in Urology: A Collaborative Review (2021)Value-Based Healthcare in Uro…Economic evaluation of nivolumab as a second‐line treatment for advanced renal cell carcinoma from US and C hinese perspectives (2017)Economic evaluation of nivolu…The GRACE Checklist: A Validated Assessment Tool for High Quality Observational Studies of Comparative Effectiveness (2016)The GRACE Checklist: A Valida…Net Health Benefits (1998)Projections of the Cost of Cancer Care in the United States: 2010-2020 (2011)The Financial Toxicity of Cancer Treatment: A Pilot Study Assessing Out-of-Pocket Expenses and the Insured Cancer Patient's Experience (2013)Essential medicines for universal health coverage (2016)Financial Hardships Experienced by Cancer Survivors: A Systematic Review (2016)Updating the American Society of Clinical Oncology Value Framework: Revisions and Reflections in Response to Comments Received (2016)Which clinical studies provide the best evidence? (2000)The GRACE Checklist for Rating the Quality of Observational Studies of Comparative Effectiveness: A Tale of Hope and Caution (2014)Measuring the Value of Prescription Drugs (2015)Methodological quality checklist for studies based on observational methodology (MQCOM) (2019)Improving Transparency to Build Trust in Real-World Secondary Data Studies for Hypothesis Testing—Why, What, and How: Recommendations and a Road Map from the Real-World Evidence Transparency Initiative (2020)Real-World Evidence: Bridging Gaps in Evidence to Guide Payer Decisions (2020)Updating Cost-Effectiveness — The Curious Resilience of the $50,000-per-QALY Threshold (2014)A standardised, generic, validated approach to stratify the magnitude of clinical benefit that can be anticipated from anti-cancer therapies: the European Society for Medical Oncology Magnitude of Clinical Benefit Scale (ESMO-MCBS) (2015)Cost‐effectiveness analysis of cabozantinib as second‐line therapy in advanced hepatocellular carcinoma (2019)Cost-Effectiveness of Tucatinib in Human Epidermal Growth Factor Receptor 2–Positive Metastatic Breast Cancer From the US and Chinese Perspectives (2020)Redefining Health Care: Creating Value-based Competition on Results (2006)The NICE Cost-Effectiveness Threshold (2008)The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration (2009)The State of Cancer Care in America, 2014: A Report by the American Society of Clinical Oncology (2014)The State of Cancer Care in America, 2016: A Report by the American Society of Clinical Oncology (2016)
this work references cited by second hop

References

  • 2015American Society of Clinical Oncology Statement: A Conceptual Framework to Assess the Value of Cancer Treatment Options916 cited
  • 2012American Society of Clinical Oncology Identifies Five Key Opportunities to Improve Care and Reduce Costs: The Top Five List for Oncology650 cited

Cited by

  • 2016The GRACE Checklist: A Validated Assessment Tool for High Quality Observational Studies of Comparative Effectiveness135 cited
  • 2017Economic evaluation of nivolumab as a second‐line treatment for advanced renal cell carcinoma from US and C hinese perspectives55 cited
  • 2021Value-Based Healthcare in Urology: A Collaborative Review49 cited

Only edges whose both ends are imported exist here. Widen the year window, or show the whole map. Back to the work